Methods and compositions relating to mesenchymal stem cell exosomes

Abstract

The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.

1 - 8 . (canceled) 
     
     
         9 . A method comprising
 administering to a subject having or at risk of developing a lung disease an effective amount of isolated mesenchymal stem cell (MSC) exosomes.   
     
     
         10 - 15 . (canceled) 
     
     
         16 . The method of  claim 9 , wherein lung disease is inflammatory lung disease, lung vascular disease, or acute lung injury. 
     
     
         17 . The method of  claim 16 , wherein the inflammatory lung disease is pulmonary hypertension, asthma, bronchopulmonary dysplasia (BPD), allergy, or idiopathic pulmonary fibrosis. 
     
     
         18 . The method of  claim 16 , wherein the acute lung injury is associated with sepsis or is ventilator-induced acute respiratory distress syndrome (ARDS). 
     
     
         19 . The method of  claim 9 , wherein the subject has or is likely to develop schistosomiasis. 
     
     
         20 . The method of  claim 9 , wherein the subject is an neonate. 
     
     
         21 . The method of  claim 9 , wherein the subject is an infant. 
     
     
         22 - 23 . (canceled) 
     
     
         24 . The method of  claim 9 , wherein the subject was born prematurely. 
     
     
         25 - 27 . (canceled) 
     
     
         28 . The method of  claim 9 , wherein the isolated MSC exosomes are used together with a secondary agent. 
     
     
         29 . The method of  claim 28 , wherein the secondary agent is a steroid, an antioxidant, or inhaled nitric oxide. 
     
     
         30 - 33 . (canceled) 
     
     
         34 . The method of  claim 20 , wherein the isolated MSC exosomes are administered within 1 month of birth. 
     
     
         35 . The method of  claim 9 , wherein the isolated MSC exosomes are administered intravenously. 
     
     
         36 . The method of  claim 9 , wherein the isolated MSC exosomes are administered to lungs or trachea of the subject. 
     
     
         37 . The method, composition, use, or isolated MSC exosomes of  claim 36 , wherein the isolated MSC exosomes are administered by inhalation. 
     
     
         38 - 44 . (canceled) 
     
     
         45 . The method of  claim 9 , wherein the isolated MSC exosomes are administered repeatedly to the subject. 
     
     
         46 . (canceled) 
     
     
         47 . The method of  claim 9 , wherein the isolated MSC exosomes are administered continuously to the subject. 
     
     
         48 . The method of  claim 9 , wherein the isolated MSC exosomes are derived from cord blood MSC. 
     
     
         49 . The method  claim 9 , wherein the isolated MSC exosomes are derived from bone marrow MSC. 
     
     
         50 . (canceled) 
     
     
         51 . The method of  claim 9 , wherein the isolated MSC exosomes are allogeneic to the subject. 
     
     
         52 . The method of  claim 9 , wherein the subject is not receiving a cell or organ transplantation. 
     
     
         53 - 58 . (canceled)